OXB Stock Overview
About the company
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company’s products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson’s disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£4.44 |
| 52 Week High | UK£6.98 |
| 52 Week Low | UK£2.77 |
| Beta | 0.97 |
| 1 Month Change | -13.72% |
| 3 Month Change | 3.02% |
| 1 Year Change | -35.54% |
| 3 Year Change | -19.36% |
| 5 Year Change | -18.77% |
| Change since IPO | -82.44% |
Recent News & Updates
Recent updates
Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 15
Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings
May 02We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn
Jun 29We Think Oxford Biomedica (LON:OXB) Can Easily Afford To Drive Business Growth
Mar 09What Kind Of Shareholders Own Oxford Biomedica plc (LON:OXB)?
Feb 08Investors Who Bought Oxford Biomedica (LON:OXB) Shares Five Years Ago Are Now Up 202%
Dec 24
The Independent Non-Executive Director of Oxford Biomedica plc (LON:OXB), Andrew John Heath, Just Sold 79% Of Their Holding
Dec 02Oxford Biomedica (LON:OXB) Is In A Good Position To Deliver On Growth Plans
Dec 01Shareholder Returns
| OXB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -8.0% | -2.4% | -1.3% |
| 1Y | -35.5% | -17.9% | -5.2% |
Return vs Industry: OXB underperformed the UK Biotechs industry which returned -17.9% over the past year.
Return vs Market: OXB underperformed the UK Market which returned -5.2% over the past year.
Price Volatility
| OXB volatility | |
|---|---|
| OXB Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OXB is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: OXB's weekly volatility (6%) has been stable over the past year.
Oxford Biomedica plc Fundamentals Summary
| OXB fundamental statistics | |
|---|---|
| Market Cap | UK£427.02m |
| Earnings (TTM) | -UK£24.54m |
| Revenue (TTM) | UK£125.57m |
3.4x
P/S Ratio-17.4x
P/E RatioIs OXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXB income statement (TTM) | |
|---|---|
| Revenue | UK£125.57m |
| Cost of Revenue | UK£49.68m |
| Gross Profit | UK£75.89m |
| Other Expenses | UK£100.43m |
| Earnings | -UK£24.54m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 60.43% |
| Net Profit Margin | -19.54% |
| Debt/Equity Ratio | 26.3% |
How did OXB perform over the long term?
See historical performance and comparison